Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

The purpose of the study is to see if daily and twice daily administration of BIIB021 is tolerated in patients with advanced solid tumors.

Key facts

Study ID

NCT00618735

Run by

Biogen

People needed

68

Starts

2008-02-01

Expected to finish

2010-12-01

Last updated by the study team

2016-12-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with histologically or cytologically confirmed solid tumor who have failed or refused standard therapies or for which no approved therapy is available.
• Age greater than or equal to 18 years at the time of informed consent. ECOG performance status of less than or equal to 2. Lab values consistent with adequate renal, hepatic, and bone marrow functions.

You may not qualify if…

• Prior antitumor therapies, including prior experimental agents or approved antitumor small molecules and biologics within 28 days and all associated toxicities resolved to eligibility levels.
• Subjects with known brain metastases. Concurrent severe or uncontrolled medical disease. Must utilize effective contraception.

Where it is running

• Research Site — Encinitas, California, United States
• Research Site — Santa Monica, California, United States
• Research Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.